A prospective observational trial on emesis in radiotherapy: Analysis of 1020 patients recruited in 45 Italian radiation oncology centres

Maranzano, Ernesto; Angelis, Verena De; Pergolizzi, Stefano; Lupattelli, Marco; Frata, Paolo; Spagnesi, S.; Frisio, Maria Luisa; Mandoliti, Giovanni; Malinverni, Giuseppe; Trippa, Fabio; Fabbietti, Letizia; Parisi, Salvatore; Palma, Antonella Di; Vecchi, Pietro De; Renzis, Costantino De; Giorgetti, Celestino; Bergami, Tiziano; Orecchia, Roberto; Portaluri, Maurizio; Signor, M.; Gennaro, Davide Di

doi:10.1016/j.radonc.2009.11.001

Cited by 80 publications

(62 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These data are in line with a recently published prospective observational trial on emesis in radiotherapy from Italy: nausea occurred in 51.7% and emesis in 22.5% of the 125 patients receiving CRT compared with 23.7% and 9.2%, respectively, of the 879 patients treated with radiotherapy alone [16]. In a study on head and neck cancer patients treated with intensity modulated radiation therapy, 65% of the 23 patients with concurrent chemotherapy suffered from nausea (grade 1: 35%; grade 2: 30%) compared with 50% (grade 1) of the 20 patients with radiotherapy alone [17].…”

Section: Discussionsupporting

confidence: 90%

“…There were no differences between the efficacy of the 5-HT3 antagonists used, namely ondansetron and granisetron, which are thought to have an equivalent effect at prescribed doses [15]. In the Italian trial, an antiemetic drug was given to a minority (prophylactic in 12.4%, symptomatic in 4.6%), thus, confirming the radiation oncologists' attitude in underestimating radiotherapy-induced emesis and underprescribing antiemetics [16]. Novel substances, such as the neurokinin-1 receptor antagonist aprepitant, have been established as potent prophylactic antiemetics in chemotherapy [2, 11, 27, 29,] but have not been evaluated in CRT.…”

Section: Discussionmentioning

confidence: 67%

“…Abdomen as the site of irradiation, which is the most evaluated parameter for nausea and emesis in radiotherapy, was not confirmed, probably because this site was underrepresented (4%) in our study. In the Italian trial, the irradiated site, i.e., upper abdomen and a field size > 400 cm 2 , were the only radiotherapy-related risk factors for nausea and emesis [16]. Instead, irradiation of the thorax and head and neck, i.e., in patients with esophagus or head and neck cancer, was associated with significant nausea and emesis.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Patient- and Treatment-Related Risk Factors for Nausea and Emesis during Concurrent Chemoradiotherapy

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 67%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Patient- and Treatment-Related Risk Factors for Nausea and Emesis during Concurrent Chemoradiotherapy

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Nos casos de tumores gastrointestinais, a mucosite intestinal reduz a absorção de nutrientes, levando à desnutrição 2 . Os eventos adversos na radioterapia são semelhantes aos da quimioterapia, com mais de 90% dos pacientes tendo vômitos como um dos principais efeitos adversos 8 . O apoio nutricional foi conseguido através do fornecimento de fórmulas nutricionais hipercalóricas e hiperproteicas.…”

Section: 34unclassified

Terapia nutricional em pacientes com câncer do aparelho digestivo

Godoi¹,

Fernandes²

2018

Int J Nutrol

View full text Add to dashboard Cite

Terapia nutricional em pacientes com câncer do aparelho digestivoNutritional therapy in patients with cancer in the digestive system RESUMO O estado nutricional é um determinante crítico do sucesso do tratamento e qualidade de vida dos pacientes com câncer. As terapias contra o câncer, incluindo cirurgia, quimioterapia e radioterapia estão associadas à desnutrição, além do que, as drogas utilizadas no tratamento para combater o câncer muitas vezes resultam em vômitos, mucosite, diarréia e disfagia. Esta pesquisa tem como objetivo principal compreender o efeito das intervenções nutricionais em pacientes com câncer no trato digestivo, analisando diversos estudos. Para a realização deste estudo foi utilizado o método de revisão da bibliografia, pesquisando-se artigos científicos das bases de dados PubMed, Bireme e Google acadêmico. Os resultados mostraram que a caquexia neoplásica é uma manifestação clínica muito comum em pacientes com câncer no trato gastrointestinal. A terapia nutricional precoce proporciona resultados benéficos em termos de minimizar a perda de peso, reduzir a deterioração do estado nutricional e da função física. Sempre que possível a primeira escolha deve ser a via oral. Porém, pacientes desnutridos ou que não conseguem ingerir a oferta calórica e proteica calculada por via oral, podem ser candidatos à nutrição enteral (NE) ou nutrição parenteral (NP). Estudos recentes têm sugerido a associação das terapias enteral e parenteral na redução das complicações pós-operatórias e na diminuição da permanência hospitalar. Palavras-chave:Enteral. Parenteral. Terapia Nutricional. Câncer. Sistema digestivo. ABSTRACTNutritional status in patients with cancer is a critical determinant of treatment success and life quality. Therapeutic approaches in cancer, including surgery, chemotherapy and radiation, are associated with malnutrition, and drugs used to treat cancer often result in vomiting, mucositis, diarrhea, and dysphagia. The main objective of this research is to understand the effect of nutritional interventions in GI cancer patients, analyzing several studies. For the accomplishment of this study we performed a systematic review of the literature, searching for scientific articles of the following databases PubMed, Bireme and Google academic. Results showed that neoplastic cachexia is a very common clinical manifestation in patients with GI cancer. Early nutritional therapy provides beneficial results in terms of minimizing weight

show abstract

“…The irradiated site (upper abdomen) and radiation field size (.400 cm 2 ) resulted as the most significant radiotherapyrelated risk factors of radiotherapy-induced emesis. 8 Another important classification that leads to the specific therapeutic approaches is based on its temporal pattern of onset. 9 The temporal pattern of CINV is divided into three types as follows:…”

mentioning

confidence: 99%

Granisetron Transdermal System in the Management of Chemotherapy-Induced Nausea and Vomiting

Kitayama

2016

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

Serotonin-type 3 receptor antagonists have been available as intravenous and oral formulations. Recently, granisetron transdermal system has won a firm position in the antiemesis of cancer chemotherapy. Its pharmacokinetic profile has been shown by pooled population analysis incorporation data. The 52 cm2 patch, which contains 34.3 mg granisetron, releases 3.3 mg daily and reaches the maximal plasma concentration after 48 hours, maintaining a 2.2 ng/mL stable average concentration over six days. This level is similar to the one obtained with daily oral 2 mg of granisetron. Three randomized clinical studies evaluating its efficacy have been published. Transdermal granisetron showed noninferiority to other formulations of serotonin-type 3 receptor antagonists for highly and moderately emetogenic – including multiday – chemotherapy. The adverse effects were not significantly different from other formulations. The system has possible applications in oral chemotherapy, radiotherapy, dexamethasone sparing, palliative care, and refractory emesis due to benign disease.

show abstract

A prospective observational trial on emesis in radiotherapy: Analysis of 1020 patients recruited in 45 Italian radiation oncology centres

Cited by 80 publications

References 17 publications

Patient- and Treatment-Related Risk Factors for Nausea and Emesis during Concurrent Chemoradiotherapy

Patient- and Treatment-Related Risk Factors for Nausea and Emesis during Concurrent Chemoradiotherapy

Terapia nutricional em pacientes com câncer do aparelho digestivo

Granisetron Transdermal System in the Management of Chemotherapy-Induced Nausea and Vomiting

Contact Info

Product

Resources

About